North America And Europe Sepsis Diagnostics Market Size, Share & Trends Analysis Report By Product, By Technology, By Pathogen, By Testing, By Method, By End Use, By Country, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
North America And Europe Sepsis Diagnostics Market Growth & Trends
The North America and Europe sepsis diagnostics market size is anticipated t%li%reach USD 1.24 billion by 2030 and is anticipated t%li%expand at a CAGR of 7.3% during the forecast period, according t%li%a new report by Grand View Research, Inc. North America experiences a significant prevalence of sepsis, making it a leading cause of hospital deaths. This high incidence drives the demand for effective diagnostic solutions. Favorable reimbursement policies als%li%encourage healthcare providers t%li%adopt advanced diagnostics, while increased awareness and public-private funding boost the development of innovative tools.
In Europe, stringent regulations ensure reliable sepsis testing methods are available, supporting market growth. The aging population, more susceptible t%li%infections, further escalates the demand for tailored diagnostic solutions. In addition, the rising healthcare spending enhances access t%li%advanced diagnostics across European countries.
The European Centre for Disease Prevention and Control (ECDC) reported in 2024 that HAIs affected around 4.5 million patients annually, with sepsis as a major consequence. In 2023, the UK government allocated approximately USD 12 million for antimicrobial resistance (AMR) research, directly aiding sepsis management initiatives. Moreover, projected federal funding for sepsis-related programs in the U.S. was expected t%li%exceed USD 50 million in 2024, aimed at improving diagnostic technologies and reducing mortality rates associated with sepsis.
North America And Europe Sepsis Diagnostics Market Report Highlights
North America And Europe Sepsis Diagnostics Market Growth & Trends
The North America and Europe sepsis diagnostics market size is anticipated t%li%reach USD 1.24 billion by 2030 and is anticipated t%li%expand at a CAGR of 7.3% during the forecast period, according t%li%a new report by Grand View Research, Inc. North America experiences a significant prevalence of sepsis, making it a leading cause of hospital deaths. This high incidence drives the demand for effective diagnostic solutions. Favorable reimbursement policies als%li%encourage healthcare providers t%li%adopt advanced diagnostics, while increased awareness and public-private funding boost the development of innovative tools.
In Europe, stringent regulations ensure reliable sepsis testing methods are available, supporting market growth. The aging population, more susceptible t%li%infections, further escalates the demand for tailored diagnostic solutions. In addition, the rising healthcare spending enhances access t%li%advanced diagnostics across European countries.
The European Centre for Disease Prevention and Control (ECDC) reported in 2024 that HAIs affected around 4.5 million patients annually, with sepsis as a major consequence. In 2023, the UK government allocated approximately USD 12 million for antimicrobial resistance (AMR) research, directly aiding sepsis management initiatives. Moreover, projected federal funding for sepsis-related programs in the U.S. was expected t%li%exceed USD 50 million in 2024, aimed at improving diagnostic technologies and reducing mortality rates associated with sepsis.
North America And Europe Sepsis Diagnostics Market Report Highlights
- Based on product, blood culture media held over 30.0% market share in 2023, while assay kits and reagents are poised for lucrative growth from 2025 t%li%2030 onwards
- Microbiology led the technology segment in 2024, while molecular diagnostics are anticipated t%li%witness the fastest rate of 9.3% over the forecast period
- Based on pathogen, bacterial sepsis held the largest market share in 2024, driven by significant mortality rates, rising HAIs, and technological advancements. It is als%li%expected t%li%grow at the fastest CAGR over the forecast period
- Based on testing, POC testing is expected t%li%grow at a staggering 9.6% CAGR as laboratory testing led the testing segment
- Based on method, automated diagnostic methods are expected t%li%grow at the fastest CAGR over the forecast period
- The U.S. dominated the North America sepsis diagnostics market as the shift t%li%value-based care promotes early detection, while supportive reimbursement, increased awareness, and government initiatives enhance sepsis management innovations.
- The UK sepsis diagnostics market is expected t%li%grow at the fastest rate of 8.1% over the forecast period in the Europe market
- In March 2024, BD collaborated with GOCC in Poland t%li%enhance access t%li%advanced bloodstream infection testing, deploying state-of-the-art microbiology equipment across over 150 hospitals and clinics for improved sepsis management
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Pathogen
1.2.4. Testing
1.2.5. Method
1.2.6. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: PRODUCT BUSINESS ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Instruments
4.4.1. Instruments Market, 2018 - 2030 (USD Million)
4.5. Blood Culture Media
4.5.1. Blood Culture Media Market, 2018 - 2030 (USD Million)
4.6. Assay Kits and Reagents
4.6.1. Assay Kits and Reagents Market, 2018 - 2030 (USD Million)
4.7. Software
4.7.1. Software Market, 2018 - 2030 (USD Million)
CHAPTER 5. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY BUSINESS ANALYSIS
5.1. Technology Market Share, 2024 & 2030
5.2. Technology Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.4. Microbiology
5.4.1. Microbiology Market, 2018 - 2030 (USD Million)
5.5. Molecular Diagnostics
5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
5.5.2. Polymerase Chain Reaction (PCR)
5.5.2.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Million)
5.5.3. DNA Microarrays
5.5.3.1. DNA Microarrays Market, 2018 - 2030 (USD Million)
5.5.4. Syndromic Panel Testing
5.5.4.1. Syndromic Panel Testing Market, 2018 - 2030 (USD Million)
5.5.5. Others
5.5.5.1. Others Market, 2018 - 2030 (USD Million)
5.6. Immunoassays
5.6.1. Immunoassays Market, 2018 - 2030 (USD Million)
5.7. Flow Cytometry
5.7.1. Flow Cytometry Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: PATHOGEN BUSINESS ANALYSIS
6.1. Pathogen Market Share, 2024 & 2030
6.2. Pathogen Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
6.4. Bacterial Sepsis
6.4.1. Bacterial Sepsis Market, 2018 - 2030 (USD Million)
6.4.2. Gram-positive Bacteria
6.4.2.1. Gram-positive Bacteria Market, 2018 - 2030 (USD Million)
6.4.3. Gram-negative Bacteria
6.4.3.1. Gram-negative Bacteria Market, 2018 - 2030 (USD Million)
6.5. Fungal Sepsis
6.5.1. Fungal Sepsis Market, 2018 - 2030 (USD Million)
6.6. Viral Sepsis
6.6.1. Viral Sepsis Market, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: TESTING BUSINESS ANALYSIS
7.1. Testing Market Share, 2024 & 2030
7.2. Testing Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Testing, 2018 to 2030 (USD Million)
7.4. Laboratory Testing
7.4.1. Laboratory Testing Market, 2018 - 2030 (USD Million)
7.5. PoC Testing
7.5.1. PoC Testing Market, 2018 - 2030 (USD Million)
CHAPTER 8. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: METHOD BUSINESS ANALYSIS
8.1. Method Market Share, 2024 & 2030
8.2. Method Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Method, 2018 to 2030 (USD Million)
8.4. Automated Diagnostics
8.4.1. Automated Diagnostics Market, 2018 - 2030 (USD Million)
8.5. Conventional Diagnostics
8.5.1. Conventional Diagnostics Market, 2018 - 2030 (USD Million)
CHAPTER 9. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: END USE BUSINESS ANALYSIS
9.1. End Use Market Share, 2024 & 2030
9.2. End Use Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
9.4. Hospitals & Clinics
9.4.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
9.5. Pathology & Reference Laboratories
9.5.1. Pathology & Reference Laboratories Market, 2018 - 2030 (USD Million)
9.6. Research Institutes and Others
9.6.1. Research Institutes and Others Market, 2018 - 2030 (USD Million)
CHAPTER 10. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
10.4. North America
10.4.1. North America Sepsis Diagnostics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
10.4.2. U.S.
10.4.2.1. Key Country Dynamics
10.4.2.2. Regulatory Framework
10.4.2.3. Competitive Insights
10.4.2.4. U.S. Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.3. Canada
10.4.3.1. Key Country Dynamics
10.4.3.2. Regulatory Framework
10.4.3.3. Competitive Insights
10.4.3.4. Canada Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5. Europe
10.5.1. Europe Sepsis Diagnostics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
10.5.2. UK
10.5.2.1. Key Country Dynamics
10.5.2.2. Regulatory Framework
10.5.2.3. Competitive Insights
10.5.2.4. UK Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.3. Germany
10.5.3.1. Key Country Dynamics
10.5.3.2. Regulatory Framework
10.5.3.3. Competitive Insights
10.5.3.4. Germany Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.4. France
10.5.4.1. Key Country Dynamics
10.5.4.2. Regulatory Framework
10.5.4.3. Competitive Insights
10.5.4.4. France Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.5. Italy
10.5.5.1. Key Country Dynamics
10.5.5.2. Regulatory Framework
10.5.5.3. Competitive Insights
10.5.5.4. Italy Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.6. Spain
10.5.6.1. Key Country Dynamics
10.5.6.2. Regulatory Framework
10.5.6.3. Competitive Insights
10.5.6.4. Spain Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.7. Russia
10.5.7.1. Key Country Dynamics
10.5.7.2. Regulatory Framework
10.5.7.3. Competitive Insights
10.5.7.4. Russia Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.8. Norway
10.5.8.1. Key Country Dynamics
10.5.8.2. Regulatory Framework
10.5.8.3. Competitive Insights
10.5.8.4. Norway Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.9. Denmark
10.5.9.1. Key Country Dynamics
10.5.9.2. Regulatory Framework
10.5.9.3. Competitive Insights
10.5.9.4. Denmark Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.10. Sweden
10.5.10.1. Key Country Dynamics
10.5.10.2. Regulatory Framework
10.5.10.3. Competitive Insights
10.5.10.4. Sweden Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Participant Overview
11.2. Company Market Position Analysis
11.3. Company Categorization
11.4. Strategy Mapping
11.5. Company Profiles/Listing
11.5.1. BD
11.5.1.1. Overview
11.5.1.2. Financial Performance
11.5.1.3. Product Benchmarking
11.5.1.4. Strategic Initiatives
11.5.2. bioMйrieux SA
11.5.2.1. Overview
11.5.2.2. Financial Performance
11.5.2.3. Product Benchmarking
11.5.2.4. Strategic Initiatives
11.5.3. Thermo Fisher Scientific Inc.
11.5.3.1. Overview
11.5.3.2. Financial Performance
11.5.3.3. Product Benchmarking
11.5.3.4. Strategic Initiatives
11.5.4. Beckman Coulter, Inc. (Danaher Corporation)
11.5.4.1. Overview
11.5.4.2. Financial Performance
11.5.4.3. Product Benchmarking
11.5.4.4. Strategic Initiatives
11.5.5. F. Hoffmann-La Roche Ltd
11.5.5.1. Overview
11.5.5.2. Financial Performance
11.5.5.3. Product Benchmarking
11.5.5.4. Strategic Initiatives
11.5.6. Cepheid
11.5.6.1. Overview
11.5.6.2. Financial Performance
11.5.6.3. Product Benchmarking
11.5.6.4. Strategic Initiatives
11.5.7. Luminex Corp.
11.5.7.1. Overview
11.5.7.2. Financial Performance
11.5.7.3. Product Benchmarking
11.5.7.4. Strategic Initiatives
11.5.8. Koninklijke Philips N.V.
11.5.8.1. Overview
11.5.8.2. Financial Performance
11.5.8.3. Product Benchmarking
11.5.8.4. Strategic Initiatives
11.5.9. Bruker
11.5.9.1. Overview
11.5.9.2. Financial Performance
11.5.9.3. Product Benchmarking
11.5.9.4. Strategic Initiatives
11.5.10. Immunexpress Inc.
11.5.10.1. Overview
11.5.10.2. Financial Performance
11.5.10.3. Product Benchmarking
11.5.10.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Pathogen
1.2.4. Testing
1.2.5. Method
1.2.6. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: PRODUCT BUSINESS ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Instruments
4.4.1. Instruments Market, 2018 - 2030 (USD Million)
4.5. Blood Culture Media
4.5.1. Blood Culture Media Market, 2018 - 2030 (USD Million)
4.6. Assay Kits and Reagents
4.6.1. Assay Kits and Reagents Market, 2018 - 2030 (USD Million)
4.7. Software
4.7.1. Software Market, 2018 - 2030 (USD Million)
CHAPTER 5. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY BUSINESS ANALYSIS
5.1. Technology Market Share, 2024 & 2030
5.2. Technology Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.4. Microbiology
5.4.1. Microbiology Market, 2018 - 2030 (USD Million)
5.5. Molecular Diagnostics
5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
5.5.2. Polymerase Chain Reaction (PCR)
5.5.2.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Million)
5.5.3. DNA Microarrays
5.5.3.1. DNA Microarrays Market, 2018 - 2030 (USD Million)
5.5.4. Syndromic Panel Testing
5.5.4.1. Syndromic Panel Testing Market, 2018 - 2030 (USD Million)
5.5.5. Others
5.5.5.1. Others Market, 2018 - 2030 (USD Million)
5.6. Immunoassays
5.6.1. Immunoassays Market, 2018 - 2030 (USD Million)
5.7. Flow Cytometry
5.7.1. Flow Cytometry Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: PATHOGEN BUSINESS ANALYSIS
6.1. Pathogen Market Share, 2024 & 2030
6.2. Pathogen Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
6.4. Bacterial Sepsis
6.4.1. Bacterial Sepsis Market, 2018 - 2030 (USD Million)
6.4.2. Gram-positive Bacteria
6.4.2.1. Gram-positive Bacteria Market, 2018 - 2030 (USD Million)
6.4.3. Gram-negative Bacteria
6.4.3.1. Gram-negative Bacteria Market, 2018 - 2030 (USD Million)
6.5. Fungal Sepsis
6.5.1. Fungal Sepsis Market, 2018 - 2030 (USD Million)
6.6. Viral Sepsis
6.6.1. Viral Sepsis Market, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: TESTING BUSINESS ANALYSIS
7.1. Testing Market Share, 2024 & 2030
7.2. Testing Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Testing, 2018 to 2030 (USD Million)
7.4. Laboratory Testing
7.4.1. Laboratory Testing Market, 2018 - 2030 (USD Million)
7.5. PoC Testing
7.5.1. PoC Testing Market, 2018 - 2030 (USD Million)
CHAPTER 8. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: METHOD BUSINESS ANALYSIS
8.1. Method Market Share, 2024 & 2030
8.2. Method Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Method, 2018 to 2030 (USD Million)
8.4. Automated Diagnostics
8.4.1. Automated Diagnostics Market, 2018 - 2030 (USD Million)
8.5. Conventional Diagnostics
8.5.1. Conventional Diagnostics Market, 2018 - 2030 (USD Million)
CHAPTER 9. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: END USE BUSINESS ANALYSIS
9.1. End Use Market Share, 2024 & 2030
9.2. End Use Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
9.4. Hospitals & Clinics
9.4.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
9.5. Pathology & Reference Laboratories
9.5.1. Pathology & Reference Laboratories Market, 2018 - 2030 (USD Million)
9.6. Research Institutes and Others
9.6.1. Research Institutes and Others Market, 2018 - 2030 (USD Million)
CHAPTER 10. NORTH AMERICA AND EUROPE SEPSIS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
10.4. North America
10.4.1. North America Sepsis Diagnostics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
10.4.2. U.S.
10.4.2.1. Key Country Dynamics
10.4.2.2. Regulatory Framework
10.4.2.3. Competitive Insights
10.4.2.4. U.S. Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.3. Canada
10.4.3.1. Key Country Dynamics
10.4.3.2. Regulatory Framework
10.4.3.3. Competitive Insights
10.4.3.4. Canada Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5. Europe
10.5.1. Europe Sepsis Diagnostics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
10.5.2. UK
10.5.2.1. Key Country Dynamics
10.5.2.2. Regulatory Framework
10.5.2.3. Competitive Insights
10.5.2.4. UK Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.3. Germany
10.5.3.1. Key Country Dynamics
10.5.3.2. Regulatory Framework
10.5.3.3. Competitive Insights
10.5.3.4. Germany Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.4. France
10.5.4.1. Key Country Dynamics
10.5.4.2. Regulatory Framework
10.5.4.3. Competitive Insights
10.5.4.4. France Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.5. Italy
10.5.5.1. Key Country Dynamics
10.5.5.2. Regulatory Framework
10.5.5.3. Competitive Insights
10.5.5.4. Italy Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.6. Spain
10.5.6.1. Key Country Dynamics
10.5.6.2. Regulatory Framework
10.5.6.3. Competitive Insights
10.5.6.4. Spain Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.7. Russia
10.5.7.1. Key Country Dynamics
10.5.7.2. Regulatory Framework
10.5.7.3. Competitive Insights
10.5.7.4. Russia Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.8. Norway
10.5.8.1. Key Country Dynamics
10.5.8.2. Regulatory Framework
10.5.8.3. Competitive Insights
10.5.8.4. Norway Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.9. Denmark
10.5.9.1. Key Country Dynamics
10.5.9.2. Regulatory Framework
10.5.9.3. Competitive Insights
10.5.9.4. Denmark Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.10. Sweden
10.5.10.1. Key Country Dynamics
10.5.10.2. Regulatory Framework
10.5.10.3. Competitive Insights
10.5.10.4. Sweden Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Participant Overview
11.2. Company Market Position Analysis
11.3. Company Categorization
11.4. Strategy Mapping
11.5. Company Profiles/Listing
11.5.1. BD
11.5.1.1. Overview
11.5.1.2. Financial Performance
11.5.1.3. Product Benchmarking
11.5.1.4. Strategic Initiatives
11.5.2. bioMйrieux SA
11.5.2.1. Overview
11.5.2.2. Financial Performance
11.5.2.3. Product Benchmarking
11.5.2.4. Strategic Initiatives
11.5.3. Thermo Fisher Scientific Inc.
11.5.3.1. Overview
11.5.3.2. Financial Performance
11.5.3.3. Product Benchmarking
11.5.3.4. Strategic Initiatives
11.5.4. Beckman Coulter, Inc. (Danaher Corporation)
11.5.4.1. Overview
11.5.4.2. Financial Performance
11.5.4.3. Product Benchmarking
11.5.4.4. Strategic Initiatives
11.5.5. F. Hoffmann-La Roche Ltd
11.5.5.1. Overview
11.5.5.2. Financial Performance
11.5.5.3. Product Benchmarking
11.5.5.4. Strategic Initiatives
11.5.6. Cepheid
11.5.6.1. Overview
11.5.6.2. Financial Performance
11.5.6.3. Product Benchmarking
11.5.6.4. Strategic Initiatives
11.5.7. Luminex Corp.
11.5.7.1. Overview
11.5.7.2. Financial Performance
11.5.7.3. Product Benchmarking
11.5.7.4. Strategic Initiatives
11.5.8. Koninklijke Philips N.V.
11.5.8.1. Overview
11.5.8.2. Financial Performance
11.5.8.3. Product Benchmarking
11.5.8.4. Strategic Initiatives
11.5.9. Bruker
11.5.9.1. Overview
11.5.9.2. Financial Performance
11.5.9.3. Product Benchmarking
11.5.9.4. Strategic Initiatives
11.5.10. Immunexpress Inc.
11.5.10.1. Overview
11.5.10.2. Financial Performance
11.5.10.3. Product Benchmarking
11.5.10.4. Strategic Initiatives
